Abstract
The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Current Drug Therapy
Title:Complications of Anti-Vascular Endothelial Growth Factor Drugs
Volume: 7 Issue: 2
Author(s): Michael Tolentino
Affiliation:
Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage
Abstract: The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.
Export Options
About this article
Cite this article as:
Tolentino Michael, Complications of Anti-Vascular Endothelial Growth Factor Drugs, Current Drug Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157488512800675959
DOI https://dx.doi.org/10.2174/157488512800675959 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Circulating Biomarkers Determining Inflammation in Atherosclerosis Progression
Current Medicinal Chemistry Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Current Diabetes Reviews Hypertension in Obesity: Novel Insights
Current Hypertension Reviews Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Modulation of Inducible Nitric Oxide Synthase Activation by Immuno-suppressive Drugs
Current Drug Metabolism Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research
Current Diabetes Reviews Ventricular Extrasystoles after First Dose of Sofosbuvir in a Patient Treated with Propranolol but not with Amiodarone: A Case Report
Reviews on Recent Clinical Trials Piroxicam: Source for Synthesis of Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Standards and Novel Therapeutic Options in the Treatment of Patients with Soft Tissue Sarcoma
Reviews on Recent Clinical Trials Clinical and Forensic Aspects of Pharmacobezoars
Current Drug Research Reviews Myocardial Perfusion SPECT Imaging in Patients after Coronary Revascularization
Vascular Disease Prevention (Discontinued) Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances
Current Hypertension Reviews Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia
Current Diabetes Reviews Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Multi-Aspect Candidates for Repositioning: Data Fusion Methods Using Heterogeneous Information Sources
Current Medicinal Chemistry Stress and Angiotensin II: Novel Therapeutic Opportunities
Current Drug Targets - CNS & Neurological Disorders Preface
Current Cancer Drug Targets Editorial [Hot Topic:Therapeutic Potential of Peptide Motifs - Part V (Executive Guest Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Binge Eating Disorder and Food Addiction
Current Drug Abuse Reviews